Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease

NCT02847052 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT02847052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02847052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease
Lead sponsor
Nantes University Hospital
Phase
Observational
Overall status
Completed
Start date
August 31, 2014
Completion date
March 16, 2022
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory bowel disease